Literature DB >> 17220551

Neuraminidase inhibitors reduce nitric oxide production in influenza virus-infected and gamma interferon-activated RAW 264.7 macrophages.

Tomas Kacergius1, Arvydas Ambrozaitis, Yuping Deng, Stefan Gravenstein.   

Abstract

The influenza virus (influenza) infection causes an intense infiltration of pulmonary tissues by macrophages, which abundantly generate a free radical, nitric oxide (NO) resulting in lung damage. Neuraminidase inhibitors (NIs) restrict influenza virus replication but whether they can suppress NO production within macrophages is unknown. RAW 264.7 macrophages were exposed to interferon-gamma (IFN-gamma), live influenza (A/PR/8/34) or a combination of both and were treated with NIs (oseltamivir or zanamivir). Results revealed that the drugs reduced a synergy between influenza and IFN-gamma in NO synthesis within the cells at all of the used concentrations (0.01, 0.1, 1 microg/ml). In contrast to zanamivir, this effect occurred in a concentration-dependent manner with oseltamivir treatment. On the other hand, all concentrations of zanamivir significantly suppressed NO production in comparison to that upon the combined exposure only (p < 0.05). Both compounds also considerably decreased NO generation in the IFN-gamma-stimulated macrophages, and zanamivir in the influenza-infected cells as well. However, neither of the drugs inhibited iNOS mRNA expression in the cells containing these stimulants. Additionally, the data indicate that a prodrug oseltamivir can be activated in vitro within the macrophage cultures. These findings are important for designing treatment approaches to limit pulmonary inflammation during influenza infection.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17220551

Source DB:  PubMed          Journal:  Pharmacol Rep        ISSN: 1734-1140            Impact factor:   3.024


  6 in total

1.  Dependence of pathogen molecule-induced toll-like receptor activation and cell function on Neu1 sialidase.

Authors:  Schammim Ray Amith; Preethi Jayanth; Susan Franchuk; Sarah Siddiqui; Volkan Seyrantepe; Katrina Gee; Sameh Basta; Rudi Beyaert; Alexey V Pshezhetsky; Myron R Szewczuk
Journal:  Glycoconj J       Date:  2009-12       Impact factor: 2.916

2.  Zanamivir Diminishes Lung Damage in Influenza A Virus-infected Mice by Inhibiting Nitric Oxide Production.

Authors:  Birutė Zablockienė; Tomas Kačergius; Arvydas Ambrozaitis; Edvardas Žurauskas; Maksim Bratchikov; Laimutė Jurgauskienė; Rolandas Zablockis; Stefan Gravenstein
Journal:  In Vivo       Date:  2018 May-Jun       Impact factor: 2.155

3.  Effective in Vivo Targeting of Influenza Virus through a Cell-Penetrating/Fusion Inhibitor Tandem Peptide Anchored to the Plasma Membrane.

Authors:  T N Figueira; M T Augusto; K Rybkina; D Stelitano; M G Noval; O E Harder; A S Veiga; D Huey; C A Alabi; S Biswas; S Niewiesk; A Moscona; N C Santos; M A R B Castanho; M Porotto
Journal:  Bioconjug Chem       Date:  2018-09-14       Impact factor: 4.774

4.  Viral replication rate regulates clinical outcome and CD8 T cell responses during highly pathogenic H5N1 influenza virus infection in mice.

Authors:  Yasuko Hatta; Karen Hershberger; Kyoko Shinya; Sean C Proll; Richard R Dubielzig; Masato Hatta; Michael G Katze; Yoshihiro Kawaoka; M Suresh
Journal:  PLoS Pathog       Date:  2010-10-07       Impact factor: 6.823

5.  Increased inducible nitric oxide synthase expression in organs is associated with a higher severity of H5N1 influenza virus infection.

Authors:  Simon Burggraaf; John Bingham; Jean Payne; Wayne G Kimpton; John W Lowenthal; Andrew G D Bean
Journal:  PLoS One       Date:  2011-01-19       Impact factor: 3.240

6.  Assessment of Mexican Arnica (Heterotheca inuloides Cass) and Rosemary (Rosmarinus officinalis) Extracts on Dopamine and Selected Biomarkers of Oxidative Stress in Stomach and Brain of Salmonella typhimurium Infected rats.

Authors:  David Calderón Guzmàn; Maribel Ortiz Herrera; Norma Osnaya Brizuela; Gerardo Barragàn Mejía; Ernestina Hernàndez García; Hugo Juàrez Olguín; Armando Valenzuela Peraza; Norma Labra Ruíz; Daniel Santamaría Del Angel
Journal:  Pharmacogn Mag       Date:  2017-04-18       Impact factor: 1.085

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.